About
Iscaffpharma’s mission is to establish the scaffold technology as a gold standard for cancer drug development. We also aim to develop own successful treatments for aggressive cancer using our proprietary technology with human and synthetic scaffolds that mimic true human cancer microenvironment. The over-all result being increased success rate in clinical development of cancer drugs.
Vision & Mission
Cancer remains a major health issue through-out the world and rates are increasing.
Despite the progress that has been made there is a high unmet need to cure aggressive forms of cancer. Our vision is to cure cancer by generating precision medicin
Our mission is to establish the scaffold technology as gold standard for cancer drug development and develop own successful treatments for aggressive cancer.
About ISCAFFPHARMA
Iscaffpharma is a Bio-Tech company founded in Gothenburg, Sweden, focusing on developing better treatments for aggressive cancers. The development is based on research by professor Göran Landberg and professor Anders Ståhlberg at Sahlgrenska Cancer Center. The research has shown that the scaffold (environment) of the tumour impacts the aggressiveness of cancers. Iscaffpharma has developed this technology into a robust and effecient platform to improve success rate in clinical development of treatments for aggressive cancer.
We provide patient derived and synthetic scaffolds mimicking the human tumour microenvironment as a tool and platform for research and development. The 3D scaffolds can predict the efficacy of drug treatment and provide high quality data to support decision on which drugs to move into clinical programs.
Substantial R&D funding has been received by Iscaffpharma being part in Vinnova grant (45 million Skr) – challenge driven innovation (UDI 3), Eurostar project with a total budget of 12 MSEK. Initial collaboration agreements with cancer drug developing companies have been established. The research has generated an approved patent and additional patent applications are filed.
In the research groups of Göran Landberg and Anders Ståhlberg more than 25 Phd’s are employed.
Team
Sara Malcus – Interim CEO and Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Göran Landberg – CSO & Board Member
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Göran Landberg – CSO & Board Member
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Peter Olofsson-Sahl – Business Developer
Experienced entrepreneur with a PhD from Lund University and an executive MBA from the GöteborgSchool of Economics and Law. Founder of biotech Redoxis and associate professor in medicine at University West in Sweden. Extensive expertise in preclinical drug development and project management of international R&D projects.
Peter Olofsson-Sahl – Business Developer
Experienced entrepreneur with a PhD from Lund University and an executive MBA from the GöteborgSchool of Economics and Law. Founder of biotech Redoxis and associate professor in medicine at University West in Sweden.Extensive expertise in preclinical drug development and project management of international R&D projects.
Anders Ståhlberg – CTO
Founder of Iscaff Pharma, Professor, is working as principal investigator at Sahlgrenska Cancer Center, University of Gothenburg and Clinical Pathology and Genetics, Sahlgrenska University Hospital. His research is focused on breast cancer and sarcomas, including childhood sarcomas. Anders has developed several molecular approaches for gene expression profiling and mutation analysis, especially at the single-cell and single-molecule level resulting in several patents and products.
Anders Ståhlberg – CTO
Founder of Iscaff Pharma, Professor, is working as principal investigator at Sahlgrenska Cancer Center, University of Gothenburg and Clinical Pathology and Genetics, Sahlgrenska University Hospital. His research is focused on breast cancer and sarcomas, including childhood sarcomas. Anders has developed several molecular approaches for gene expression profiling and mutation analysis, especially at the single-cell and single-molecule level resulting in several patents and products.
Elena Garre – Lead Scientist
Experienced researcher, PhD, in molecular biology and gene expression regulation. Combining deep expertise in manipulation and cultivation of microorganisms and human cells with molecular genetics and, protein and RNA biochemistry.
Expertise in transcriptional and post-transcriptional regulation studies, RNA binding proteins, RNA metabolism, RNA-proteins aggregates, LNP-mediated RNA delivery to human cells and human cell culture techniques. Elena strives to deeply understand the human cancer biology and to ultimately bring new effective treatments to patients.
Elena Garre – Lead Scientist
Experienced researcher, PhD, in molecular biology and gene expression regulation. Combining deep expertise in manipulation and cultivation of microorganisms and human cells with molecular genetics and, protein and RNA biochemistry.
Expertise in transcriptional and post-transcriptional regulation studies, RNA binding proteins, RNA metabolism, RNA-proteins aggregates, LNP-mediated RNA delivery to human cells and human cell culture techniques. Elena strives to deeply understand the human cancer biology and to ultimately bring new effective treatments to patients.
Thais Fenz Araujo – Senior Scientist
PhD in medical sciences (Genetics). Experienced in research projects, laboratory management and molecular diagnosis of genetic diseases. Thais goal is to contribute to the progress of the healthcare sector using my knowledge and skills in research and education fields.
Thais Fenz Araujo – Senior Scientist
PhD in medical sciences (Genetics). Experienced in research projects, laboratory management and molecular diagnosis of genetic diseases. Thais goal is to contribute to the progress of the healthcare sector using my knowledge and skills in research and education fields.
In memorandum, – Per Setterberg
Per Setterberg – CEO
Marketing professional with a Bachelor of economy from School of business Gothenburg University and Bachelor of law from Lunds University. More than 20 years of sales and marketing experience in Life Science. Working with strategy and tactics as board member all the way to operational marketing and sales, focusing in pharmaceutical and med tech . Per strongly believes in the added value for all, from business, society and last but not least the patient.
Board of directors
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Göran Landberg – Board Member & CSO
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Göran Landberg – CMO
Founder of Iscaff Pharma, Professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Charlotta Blom – Board Member
Charlotta Blom has a comprehensive background as a researcher in academia and in the biotech industry. She previously served as a Senior Intellectual Property (IP) Business Consultant at Synergon, where she collaborated closely with Iscaff Pharma to develop and maintain strategies for protecting new ideas and inventions. Recently, she transitioned to a role as a Patent Consultant at Bergenstråhle & Partners. In this position, she focuses on identifying, developing, and maintaining commercially relevant patent protection for life science clients by strategically managing their patent portfolios. Charlotta has managed Iscaff Pharma’s IP matters for several years and now oversees their IP strategy from the board’s perspectives.
Charlotta Blom – Board Member
Charlotta Blom has a comprehensive background as a researcher in academia and in the biotech industry. She previously served as a Senior Intellectual Property (IP) Business Consultant at Synergon, where she collaborated closely with Iscaff Pharma to develop and maintain strategies for protecting new ideas and inventions. Recently, she transitioned to a role as a Patent Consultant at Bergenstråhle & Partners. In this position, she focuses on identifying, developing, and maintaining commercially relevant patent protection for life science clients by strategically managing their patent portfolios. Charlotta has managed Iscaff Pharma’s IP matters for several years and now oversees their IP strategy from the board’s perspectives.
Partners and Collaborators
Iscaffpharma is part of UDI3 challenge driven innovation supported by Vinnova. Our partners are:
